Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478854 · ClinicalTrials.gov registry record · NA
Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT01478854 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 33 participants.
The verdict
NCT01478854, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The long term goal of this research is to establish whether NPC sparing RT techniques improve neurocognitive outcomes compared to conventional RT for brain tumors. If the proposed study demonstrates that NPC sparing RT is not associated with increased LR in the spared regions of the brain compared to conventional RT, it will ideally serve as the foundation for a future multi-institutional randomized controlled trial comparing neurocognitive outcomes in patients treated with NPC-sparing RT versus conventional radiation therapy.
Interventions
- DRUG Chemotherapy
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-12-27 |
| Est. Completion | 2018-04-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478854
The ClinicalTrials.gov registry entry for NCT01478854 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT01478854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478854 about?
NCT01478854 is a clinical study titled "Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide". The long term goal of this research is to establish whether NPC sparing RT techniques improve neurocognitive outcomes compared to conventional RT for brain tumors. If the proposed study demonstrates that NPC sparing RT is not associated with increased LR in the spared regions of the brain compared t...
What is the current status of trial NCT01478854?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2011-12-27. Estimated completion is 2018-04-25.
What interventions are being tested in trial NCT01478854?
The interventions under investigation include: Chemotherapy (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT01478854?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.